Cargando…

Hyperkalaemia in Heart Failure

Hyperkalaemia has become an increasingly prevalent finding in patients with heart failure (HF), especially with renin–angiotensin–aldosterone system (RAAS) inhibitors and angiotensin–neprilysin inhibitors being the cornerstone of medical therapy. Patients living with HF often have other comorbiditie...

Descripción completa

Detalles Bibliográficos
Autores principales: Ismail, Umar, Sidhu, Kiran, Zieroth, Shelley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Radcliffe Cardiology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150383/
https://www.ncbi.nlm.nih.gov/pubmed/34094588
http://dx.doi.org/10.15420/cfr.2020.29
_version_ 1783698139083964416
author Ismail, Umar
Sidhu, Kiran
Zieroth, Shelley
author_facet Ismail, Umar
Sidhu, Kiran
Zieroth, Shelley
author_sort Ismail, Umar
collection PubMed
description Hyperkalaemia has become an increasingly prevalent finding in patients with heart failure (HF), especially with renin–angiotensin–aldosterone system (RAAS) inhibitors and angiotensin–neprilysin inhibitors being the cornerstone of medical therapy. Patients living with HF often have other comorbidities, such as diabetes and chronic kidney disease, which predispose to hyperkalaemia. Until now, we have not had any reliable or tolerable therapies for the treatment of hyperkalaemia to facilitate implementation or achievement of target doses of RAAS inhibition. Patiromer sorbitex calcium and sodium zirconium cyclosilicate are two novel potassium-binding resins that have shown promise in the management of patients predisposed to developing recurrent hyperkalaemia, and their use may allow for further optimisation of guideline directed medical therapy.
format Online
Article
Text
id pubmed-8150383
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Radcliffe Cardiology
record_format MEDLINE/PubMed
spelling pubmed-81503832021-06-03 Hyperkalaemia in Heart Failure Ismail, Umar Sidhu, Kiran Zieroth, Shelley Card Fail Rev Comorbidities Hyperkalaemia has become an increasingly prevalent finding in patients with heart failure (HF), especially with renin–angiotensin–aldosterone system (RAAS) inhibitors and angiotensin–neprilysin inhibitors being the cornerstone of medical therapy. Patients living with HF often have other comorbidities, such as diabetes and chronic kidney disease, which predispose to hyperkalaemia. Until now, we have not had any reliable or tolerable therapies for the treatment of hyperkalaemia to facilitate implementation or achievement of target doses of RAAS inhibition. Patiromer sorbitex calcium and sodium zirconium cyclosilicate are two novel potassium-binding resins that have shown promise in the management of patients predisposed to developing recurrent hyperkalaemia, and their use may allow for further optimisation of guideline directed medical therapy. Radcliffe Cardiology 2021-05-12 /pmc/articles/PMC8150383/ /pubmed/34094588 http://dx.doi.org/10.15420/cfr.2020.29 Text en Copyright © 2021, Radcliffe Cardiology https://creativecommons.org/licenses/by-nc/4.0/This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.
spellingShingle Comorbidities
Ismail, Umar
Sidhu, Kiran
Zieroth, Shelley
Hyperkalaemia in Heart Failure
title Hyperkalaemia in Heart Failure
title_full Hyperkalaemia in Heart Failure
title_fullStr Hyperkalaemia in Heart Failure
title_full_unstemmed Hyperkalaemia in Heart Failure
title_short Hyperkalaemia in Heart Failure
title_sort hyperkalaemia in heart failure
topic Comorbidities
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150383/
https://www.ncbi.nlm.nih.gov/pubmed/34094588
http://dx.doi.org/10.15420/cfr.2020.29
work_keys_str_mv AT ismailumar hyperkalaemiainheartfailure
AT sidhukiran hyperkalaemiainheartfailure
AT zierothshelley hyperkalaemiainheartfailure